drugset
drugset / Trial / NCT02254018

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

NCT02254018 ↗

Phase 1 Completed 31 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine

Timeline

Start
2002-09-01
Primary completion
2005-02-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject bivatuzumab mertansine Unknown — Intravenous

Indications

head and neck neoplasm